abstract |
The present invention relates to a novel antisense transcript of the human SLC2A1 gene (Glut1), variants and fragments thereof. The antisense transcript according to the invention can be used to modulate Glut1 expression and serve to restore Glut1, and as a therapeutic agent for treating or preventing Glut1 deficiency syndrome, or other Glut1-related disorders. , including some cancers, diabetes, Alzheimer's disease, and retinitis pigmentosa. |